Findings

What do systematic reviews say?

1,155 questions · 1,191 findings · 195 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 209 · 17.5%GRADE not reported 51 · 4.3%Very low 256 · 21.5%Low 273 · 22.9%Moderate 284 · 23.8%High 118 · 9.9%

Summary of findings: serious adverse events (HEC) when vs treatment with aprepitant + granisetron

fosaprepitant + palonosetron · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
23 studies · 16065 participants
Very low

Summary of findings: complete control of vomiting during the overall phase (HEC) when vs treatment with aprepitant + granisetron

fosnetupitant + palonosetron · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
39 studies · 21642 participants
Moderate

Summary of findings: serious adverse events (HEC) when vs treatment with aprepitant + granisetron

fosnetupitant + palonosetron · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
23 studies · 16065 participants
Very low

Summary of findings: serious adverse events (HEC) when vs treatment with aprepitant + granisetron

fosaprepitant + granisetron · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
23 studies · 16065 participants
Low

Summary of findings: serious adverse events (HEC) when vs treatment with aprepitant + granisetron

aprepitant + palonosetron · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
23 studies · 16065 participants
Very low

Summary of findings: serious adverse events (HEC) when vs treatment with aprepitant + granisetron

rolapitant + granisetron · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
23 studies · 16065 participants
Low

Summary of findings: complete control of vomiting during the overall phase (HEC) when vs treatment with aprepitant + granisetron

aprepitant + palonosetron · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
39 studies · 21642 participants
Low

Summary of findings: complete control of vomiting during the overall phase (HEC) when vs treatment with aprepitant + granisetron

aprepitant + ramosetron · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
39 studies · 21642 participants
Low

Summary of findings: complete control of vomiting during the overall phase (HEC) when vs treatment with aprepitant + granisetron

fosaprepitant + palonosetron · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
39 studies · 21642 participants
Low

Summary of findings: complete control of vomiting during the overall phase (HEC) when vs treatment with aprepitant + granisetron

netupitant + palonosetron · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
39 studies · 21642 participants
High

Summary of findings: complete control of vomiting during the overall phase (HEC) when vs treatment with aprepitant + granisetron

fosaprepitant + granisetron · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
39 studies · 21642 participants
High

Summary of findings: complete control of vomiting during the overall phase (HEC) when vs treatment with aprepitant + granisetron

aprepitant + ondansetron · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
39 studies · 21642 participants
Low

Summary of findings: complete control of vomiting during the overall phase (HEC) when vs treatment with aprepitant + granisetron

fosaprepitant + ondansetron · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
39 studies · 21642 participants
Low

Bronchial thermoplasty vs active control

Health‐related quality of life (AQLQ)Scale from: 1‐7 (higher is better) · adults with asthma

1 finding from 1 review

Bronchial thermoplasty for moderate or severe persistent asthma in adults 2014 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 429 participants
Moderate

Bronchial thermoplasty vs active control

Asthma control · adults with asthma

1 finding from 1 review

Bronchial thermoplasty for moderate or severe persistent asthma in adults 2014 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 429 participants
Moderate

Bronchial thermoplasty vs active control

Exacerbations · adults with asthma

1 finding from 1 review

Bronchial thermoplasty for moderate or severe persistent asthma in adults 2014 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 409 participants
GRADE not reported

Bronchial thermoplasty vs active control

Participants admitted to hospital because of respiratory adverse events (treatment period) · adults with asthma

Bronchial thermoplasty leads to higher participants admitted to hospital because of respiratory adverse… compared with any active control (high certainty).

1 finding from 1 review

Bronchial thermoplasty for moderate or severe persistent asthma in adults 2014 · Cochrane Headline outcomes only
RR 3.5 [1.26, 9.68]
3 studies · 429 participants
High

Bronchial thermoplasty vs active control

Participants admitted to hospital because of respiratory adverse events (post‐treatment period) · adults with asthma

Bronchial thermoplasty showed no clear difference in participants admitted to hospital because of respiratory adverse… compared with any active control (moderate certainty).

1 finding from 1 review

Bronchial thermoplasty for moderate or severe persistent asthma in adults 2014 · Cochrane Headline outcomes only
RR 1.12 [0.44, 2.85]
3 studies · 429 participants
Moderate

Bronchial thermoplasty vs active control

Use of rescue medication · adults with asthma

1 finding from 1 review

Bronchial thermoplasty for moderate or severe persistent asthma in adults 2014 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 429 participants
Low

Cognitive training vs control

Change in a global measure of cognition (composite) · participants with early‐stage Alzheimer's disease and vascular dementia

1 finding from 1 review

Cognitive training and cognitive rehabilitation for mild to moderate Alzheimer's disease and vascular dementia 2013 · Cochrane Headline outcomes only
no estimate extracted
6 studies · 173 participants
Low